scholarly article | Q13442814 |
P50 | author | Chris Ponting | Q5107785 |
Imran Ahmad | Q41788095 | ||
Joanne Edwards | Q42315840 | ||
Ian Sudbery | Q57316959 | ||
Prabhakar Rajan | Q60976609 | ||
Andreas Heger | Q30503100 | ||
Owen J Sansom | Q37382476 | ||
Hing Y Leung | Q40453449 | ||
P2093 | author name string | David Sims | |
Ernest Mui | |||
Mark Davis | |||
Ian D Pedley | |||
Janis Fleming | |||
M Eugenia M Villasevil | |||
Rhona M McMenemin | |||
P2860 | cites work | An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression | Q24313269 |
Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development | Q40651903 | ||
Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells | Q40834731 | ||
Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platforms | Q41597733 | ||
Alterations in beta-catenin expression and localization in prostate cancer | Q42813475 | ||
Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging | Q69737582 | ||
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling | Q24316697 | ||
The beta-catenin binding protein ICAT modulates androgen receptor activity | Q24337124 | ||
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer | Q24616117 | ||
RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays | Q24655562 | ||
The KEGG resource for deciphering the genome | Q27860687 | ||
Wnt/β-catenin signalling in prostate cancer | Q28269116 | ||
Integrins in cancer: biological implications and therapeutic opportunities | Q29614536 | ||
The mutational landscape of lethal castration-resistant prostate cancer | Q29614634 | ||
The development of androgen-independent prostate cancer | Q29615650 | ||
WNT signalling pathways as therapeutic targets in cancer | Q29615666 | ||
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 | ||
Abiraterone and increased survival in metastatic prostate cancer | Q29617512 | ||
Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome | Q31043876 | ||
Characterization of the small RNA transcriptomes of androgen dependent and independent prostate cancer cell line by deep sequencing | Q33770060 | ||
A comparison of massively parallel nucleotide sequencing with oligonucleotide microarrays for global transcription profiling | Q33881890 | ||
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. | Q34292287 | ||
β-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma | Q34539930 | ||
p68/DdX5 supports β-catenin & RNAP II during androgen receptor mediated transcription in prostate cancer | Q34562695 | ||
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance | Q35083279 | ||
Recurrent gene fusions in prostate cancer | Q37194503 | ||
Alternative splicing and biological heterogeneity in prostate cancer | Q37573399 | ||
Adaptation or selection--mechanisms of castration-resistant prostate cancer | Q38068116 | ||
Chemical castration and anti-androgens induce differential gene expression in prostate cancer. | Q38326753 | ||
International variation in prostate cancer incidence and mortality rates. | Q38935652 | ||
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. | Q39222325 | ||
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer | Q39541646 | ||
Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition | Q39697788 | ||
Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer | Q39700207 | ||
Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer | Q39910338 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | prostate cancer | Q181257 |
RNA sequencing | Q2542347 | ||
P304 | page(s) | 32-39 | |
P577 | publication date | 2013-08-14 | |
P1433 | published in | European Urology | Q15763991 |
P1476 | title | Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy | |
P478 | volume | 66 |